Related Experiment Videos
Should a modern antihypertensive drug possess cardioprotective properties?
1Department of Geriatrics, University of Uppsala, Sweden.
Insights
Antihypertensive drugs effectively reduce cardiovascular risks, particularly stroke. The novel calcium channel blocker mibefradil may offer enhanced cardioprotective benefits, warranting further investigation in clinical trials.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- Antihypertensive drug treatment significantly reduces cardiovascular morbidity and mortality, with notable benefits against stroke.
- While protective effects against coronary heart disease are significant, they are less pronounced than stroke prevention.
- Modern antihypertensive drugs may require additional cardioprotective properties for improved coronary heart disease outcomes.
Purpose of the Study:
- To evaluate the potential cardioprotective properties of the novel calcium channel antagonist mibefradil.
- To assess if mibefradil's unique hemodynamic profile offers additional cardiovascular benefits beyond blood pressure reduction.
- To determine the need for prospective intervention studies to confirm mibefradil's cardioprotective potential.
Main Methods:
- Review of existing literature on antihypertensive drug effects on cardiovascular outcomes.
- Analysis of mibefradil's pharmacological profile, including its dual blockade of T- and L-type calcium channels.
- Consideration of hemodynamic effects, such as arterial pressure reduction with minimal impact on cardiac output.
Main Results:
- Antihypertensive therapy demonstrably reduces stroke risk, as confirmed by trials like Syst-Eur and STONE.
- Mibefradil exhibits a vasodilating effect, lowering arterial pressure without compromising cardiac output.
- The drug's ability to block both T- and L-type calcium channels suggests a potentially favorable hemodynamic profile.
Conclusions:
- Mibefradil's pharmacodynamic profile suggests potential for additional cardioprotective benefits in hypertension management.
- Further prospective intervention studies are necessary to rigorously assess mibefradil's cardioprotective efficacy.
- The findings highlight the ongoing search for antihypertensive agents with superior cardiovascular protection.
Abstract:
PROTECTIVE EFFECTS OF ANTIHYPERTENSIVE DRUGS: Treatment of hypertension has been shown to reduce cardiovascular morbidity and mortality. This is especially true for the beneficial effect against stroke. The protective effects against coronary heart disease have also been significant but numerically less impressive than the effect against stroke. It is conceivable that a modern drug should possess cardioprotective properties in order to achieve a better protection against coronary heart disease. EFFECTS OF MIBEFRADIL: The novel calcium antagonist mibefradil, which blocks both transient (T) and long-lasting (L) calcium channels, has a hemodynamic profile which may have cardioprotective properties. Mibefradil reduces arterial pressure by a vasodilating effect with little or no effect on cardiac output. Recently reported effects of antihypertensive treatment with a calcium antagonist on stroke morbidity in the European trial on systolic hypertension (Syst-Eur) have confirmed previous findings with a calcium antagonist in the Shanghai Trial Of Nifedipine in the Elderly (STONE). Thus the pharmacodynamic profile of mibefradil might offer additional cardioprotective benefit. This possibility deserves assessment in a proper prospective intervention study.